Show notes
“I wasn't selling printers, I was selling what would make their lives easier in terms of the medical diagnostics that they were doing on a day-to-day basis.”
Ilya Burkov is Global Head of Scientific AI & Healthcare at Nebius. PhD done, Ilya has to decide what comes next. He wants to stay close to healthcare, but he's done pretending the bench is the only road. The first role he finds is business development at a medical diagnostics company, which is where the conversation gets honest about the word scientists flinch at: sales. Jon admits it feels icky coming out of a lab. Ilya's pushback is simple: clinicians are data-driven, so if your reagents genuinely improve their results, you're showing people what they've been missing. A year in the job and he never felt like a salesman.
Then his salary almost doubles and he jumps to Pando, a secure clinical messaging platform trusted by 60,000 healthcare professionals across roughly 200 NHS organizations, replacing WhatsApp and pagers right as COVID lands. While his old Randox colleagues can't get on planes to visit labs, Ilya is selling a mobile app to hospitals where a second opinion can't legally travel by text. The thread widens into whether the pandemic's forced adoption stuck, and his typewriter theory of how every tool eventually sells itself.
The back half lands on telemedicine as the entry point of care, the math of not making a patient travel two hours for a 20-minute conversation, and the quieter win: a consultant reviewing a case somewhere they may never physically reach. For anyone weighing a jump from lab to commercial, this stretch makes the case.

